Related references
Note: Only part of the references are listed.CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer
Markus Chmielewski et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
Kevin J. Curran et al.
JOURNAL OF GENE MEDICINE (2012)
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
Dirk Nagorsen et al.
EXPERIMENTAL CELL RESEARCH (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The immunoregulatory mechanisms of carcinoma for its survival and development
Caigan Du et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy
John S. Bridgeman et al.
CURRENT GENE THERAPY (2010)
Features of responding T cells in cancer and chronic infection
Peter S. Kim et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
Mathematical Modeling of Chimeric TCR Triggering Predicts the Magnitude of Target Lysis and Its Impairment by TCR Downmodulation
Scott E. James et al.
JOURNAL OF IMMUNOLOGY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Antibody recognition of a unique tumor-specific glycopeptide antigen
Cory L. Brooks et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
Dorte Lisbet Nielsen et al.
CANCER TREATMENT REVIEWS (2009)
T Cell Receptor Gene Therapy for Cancer
Thomas M. Schmitt et al.
HUMAN GENE THERAPY (2009)
The Impact of TCR-Binding Properties and Antigen Presentation Format on T Cell Responsiveness
Adam S. Chervin et al.
JOURNAL OF IMMUNOLOGY (2009)
A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity
Yangbing Zhao et al.
JOURNAL OF IMMUNOLOGY (2009)
Engineering higher affinity T cell receptors using a T cell display system
Adam S. Chervin et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane
Scott T. James et al.
JOURNAL OF IMMUNOLOGY (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Tumor-specific immune responses
Hans Schreiber
SEMINARS IN IMMUNOLOGY (2008)
Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction
Fabio Turatti et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: Implications for self-tolerance and tumor therapy
Silvie Cloosen et al.
CANCER RESEARCH (2007)
Facilitating matched pairing and expression of TCR chains introduced into human T cells
Jurgen Kuball et al.
BLOOD (2007)
A mutant chaperone converts a wild-type protein into a tumor-specific antigen
Andrea Schietinger et al.
SCIENCE (2006)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
Philipp Kiewe et al.
CLINICAL CANCER RESEARCH (2006)
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
K Brischwein et al.
MOLECULAR IMMUNOLOGY (2006)
A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry
SH Olejniczak et al.
IMMUNOLOGICAL INVESTIGATIONS (2006)
An inducible caspase 9 safety switch for T-cell therapy
KC Straathof et al.
BLOOD (2005)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
ME Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
High frequency of functionally active Melan-A-specific T cells in a patient with progressive immunoproteasome-deficient melanoma
N Meidenbauer et al.
CANCER RESEARCH (2004)
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance
ZY Yu et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity
M Chmielewski et al.
JOURNAL OF IMMUNOLOGY (2004)
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect
LJN Cooper et al.
BLOOD (2003)
A unique molecular chaperone Cosmc required for activity of the mammalian core 1 β3-galactosyltransferase
TZ Ju et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors
NM Haynes et al.
BLOOD (2002)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
HLA class I antigen abnormalities and immune escape by malignant cells
B Seliger et al.
SEMINARS IN CANCER BIOLOGY (2002)
Immunotherapy through TCR gene transfer
HWHG Kessels et al.
NATURE IMMUNOLOGY (2001)
Plat-E: an efficient and stable system for transient packaging of retroviruses
S Morita et al.
GENE THERAPY (2000)
Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production
MEM Weijtens et al.
GENE THERAPY (2000)
Share Paper
